SHOTZ study shows Forteo more effective than Zometa in bone remodelling

Data from the SHOTZ study were compared showing the mechanisms of action of Forteo (teriparatide [rDNA origin] injection) from Eli Lilly and zoledronic acid (Zometa) from Novartis that evaluated histomorphometric measurements of bone remodeling in transiliac crest bone biopsies from postmenopausal women with osteoporosis. These data were presented in an oral presentation at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, Calif. Dynamic indices of bone formation, including mineralizing surface/bone surface (MS/BS) and bone formation rate (BFR), were significantly higher in women treated with Forteo than in women treated with zoledronic acid at six months.see Dempster, D., et al. "Skeletal Histomorphometry in Patients On Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: 6�Month Results of a Randomized Clinical Trial." Abstract presented at the ASBMR 2011 Annual Meeting, Sept. 19, 2011, 3:45 PM.